C. Hara-Cleaver

Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data

H. Zhang, P. Calabresi, E. Fisher, 2008, Multiple sclerosis.

Early tolerability and safety of fingolimod in clinical practice

Jeffrey A. Cohen, R. Rudick, D. Ontaneda, 2012, Journal of the Neurological Sciences.

Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis

R. Marrie, R. Rudick, M. Horton, 2010, Neuroepidemiology.

Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

Jeffrey A. Cohen, Stephen M. Rao, Deborah M. Miller, 2020, Neurology. Clinical practice.

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

H. Zhang, G. Beck, P. Calabresi, 2009, Neurology.

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

Elizabeth Fisher, R. Rudick, E. Fisher, 2013, JAMA neurology.

Experience with fingolimod in clinical practice

Jeffrey A. Cohen, R. Rudick, D. Ontaneda, 2015, The International journal of neuroscience.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up

Jeffrey A. Cohen, D. Ontaneda, R. Fox, 2017, Multiple sclerosis journal - experimental, translational and clinical.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Jeffrey A. Cohen, D. Ontaneda, R. Fox, 2016, Multiple sclerosis and related disorders.